Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREFirst-ever approval of a CRISPR-based gene-editing therapy in the U.S. Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment Multiple authorized treatment centers activated BOSTON & ZUG, Switzerland / Dec...Read more
First-ever approval of a CRISPR-based gene-editing therapy in the U.S. Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment Multiple authorized treatment centers activated BOSTON & ZUG, Switzerland / Dec...Read more
Severe vaso-occlusive events were eliminated for 94% (30/32) of evaluable patients and all VOEs were eliminated for 88% (28/32) of evaluable patients between 6 and 18 months post-infusion LYFGENIA is the most deeply studied gene therapy for sickle cell disease with the most patients treated and...Read more
Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study These data...Read more
RAHWAY, N.J., & NUTLEY, N.J. / Dec 08, 2023 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced that the Phase 3 LEAP-001 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple...Read more
First presentation of progression-free survival (PFS) primary endpoint data show zanidatamab plus palbociclib and fulvestrant demonstrated a PFS of 67% at 6 months and a median PFS of 12 months in patients with heavily pre-treated HER2+/HR+ metastatic breast cancer (mBC) Efficacy and...Read more
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Eli Lilly | 9.78 1.66 | $598.05 |
| IDEXX Laboratories | 8.27 1.58 | $531.35 |
| Instil Bio | 6.35 2,012.77 | $6.67 |
| Lantheus | 5.18 7.56 | $73.71 |
| Science 37 | 4.69 1,954.17 | $4.93 |
| Align Technology | 4.62 2.13 | $221.23 |
| Molina Healthcare | 4.29 1.18 | $367.72 |
| ICON | 4.27 1.59 | $272.46 |
| Inspire Medical Systems | 4.19 2.60 | $165.09 |
| Cassava Sciences | 3.61 17.37 | $24.39 |
| HCA Healthcare | 3.58 1.41 | $257.53 |
| Krystal Biotech | 3.46 3.35 | $106.86 |
| Disc Medicine | 3.44 5.98 | $61.01 |
| Univerl Health Services | 3.10 2.31 | $137.45 |
| ALX Oncology | 3.01 32.54 | $12.26 |
| Intensity Therapeutics | 2.88 72.00 | $6.88 |
| Zoetis | 2.77 1.52 | $184.60 |
| Company | Volume | Last Trade |
|---|---|---|
| Therapeutic Solutions | 52,864,999 | $0.001 |
| bluebird bio | 51,855,597 | $2.86 |
| Intensity Therapeutics | 31,734,433 | $6.88 |
| Altimmune | 27,841,585 | $6.48 |
| Pfizer | 27,714,307 | $28.78 |
| Exicure | 24,620,017 | $0.52 |
| Ginkgo Bioworks | 17,811,279 | $1.36 |
| Walgreens Boots Alliance | 17,214,657 | $23.16 |
| CRISPR Therapeutics | 17,132,757 | $64.54 |
| Avalo Therapeutics | 14,463,872 | $0.05 |
| eFFECTOR Therapeutics | 14,024,760 | $0.52 |
| ImmunoGen | 13,496,602 | $29.21 |
| Bristol-Myers Squibb | 10,107,566 | $50.31 |
| Altamira Therapeutics | 9,385,806 | $0.41 |
| Veradigm | 8,734,270 | $10.07 |
| CVS Health | 8,677,714 | $75.10 |
| Elanco Animal Health | 8,619,100 | $12.80 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
